{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:40:49Z","timestamp":1777394449775,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2017,3,4]]},"abstract":"\n Secreted soluble amyloid-\u03b2 1\u201337 (A\u03b2\n 37<\/jats:sub>\n ) peptide is one of the prominent A\u03b2 forms next to A\u03b2\n 40<\/jats:sub>\n , and is found in cerebrospinal fluid (CSF) and blood. Recent studies have shown the importance of quantitation of CSF A\u03b2\n 37<\/jats:sub>\n levels in combination with A\u03b2\n 38<\/jats:sub>\n , A\u03b2\n 40<\/jats:sub>\n , and A\u03b2\n 42<\/jats:sub>\n to support the diagnosis of patients with probable Alzheimer\u2019s disease (AD), and the value of antibody to A\u03b2\n 37<\/jats:sub>\n to facilitate drug discovery studies. However, the availability of reliable and specific monoclonal antibody to A\u03b2\n 37<\/jats:sub>\n is very limited. Our aims were: 1) to generate and partially characterize rabbit monoclonal antibody (RabmAb) to A\u03b2\n 37<\/jats:sub>\n , and 2) to determine whether the antibody detects changes in A\u03b2\n 37<\/jats:sub>\n levels produced by a \u03b3-secretase modulator (GSM). Our generated RabmAb to A\u03b2\n 37<\/jats:sub>\n was found to be specific to A\u03b2\n 37<\/jats:sub>\n , since it did not react with A\u03b2\n 36<\/jats:sub>\n , A\u03b2\n 38<\/jats:sub>\n , A\u03b2\n 39<\/jats:sub>\n , A\u03b2\n 40<\/jats:sub>\n , and A\u03b2\n 42<\/jats:sub>\n in an ELISA or immunoblotting. The epitope of the antibody was contained in the seven C-terminal residues of A\u03b2\n 37<\/jats:sub>\n . The antibody was sensitive enough to measure CSF and plasma A\u03b2\n 37<\/jats:sub>\n levels in ELISA. Immunohistological studies showed the presence of A\u03b2\n 37<\/jats:sub>\n -positive deposits in the brain of AD, and Down syndrome persons diagnosed with AD. Our studies also showed that the antibody detected A\u03b2\n 37<\/jats:sub>\n increases in CSF and brains of rodents following treatment with a GSM. Thus, our antibody can be widely applied to AD research, and in a panel based approach it may have potential to support the diagnosis of probable AD, and in testing the effect of GSMs to target AD.\n <\/jats:p>","DOI":"10.3233\/jad-161207","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T09:46:42Z","timestamp":1486720002000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid-\u03b2 Peptide 1\u201337 (A\u03b2\n 37<\/sub>\n )"],"prefix":"10.1177","volume":"57","author":[{"given":"Pankaj D.","family":"Mehta","sequence":"first","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Francois","family":"Blain","sequence":"additional","affiliation":[{"name":"FORUM Pharmaceuticals, Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"Freeman","sequence":"additional","affiliation":[{"name":"FORUM Pharmaceuticals, Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Patrick","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Barshatzky","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A.","family":"Hrdlicka","sequence":"additional","affiliation":[{"name":"FORUM Pharmaceuticals, Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangita P.","family":"Mehta","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Frackowiak","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Mazur-Kolecka","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Wegiel","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Patzke","sequence":"additional","affiliation":[{"name":"FORUM Pharmaceuticals, Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Miller","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"key":"ref001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1052-5149(25)00275-8","volume":"5","author":"Wisniewski HM","year":"1995","journal-title":"Neuroimaging Clin N Am"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.17.030194.002421"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2009.218"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.4"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00818.x"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1159\/000119457"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-5-2"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-012-0801-3"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.246561"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt121"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-141986"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802912200"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.305227"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-7-61"},{"key":"ref015","first-page":"116","volume":"20","author":"Soares HD","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1021\/jm201407j"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1080\/13506120601116500"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-101341"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-009-0497-0"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.37.22908"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-006-0191-4"},{"key":"ref023","first-page":"230","volume":"57","author":"Kitamoto T","year":"1987","journal-title":"Lab Invest"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-142592"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20508"},{"key":"ref026","volume":"6","author":"Thal DR","year":"2006","journal-title":"Sci Aging Knowledge Envior"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00205-8"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.08.031"},{"key":"ref029","first-page":"33","volume":"2","author":"Wegiel J","year":"1992","journal-title":"NeuroScience News"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1007\/BF00296738"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1016\/0197-4580(91)90091-W"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0294-7"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-161207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-161207","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-161207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:03:16Z","timestamp":1777370596000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-161207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3,4]]}},"alternative-id":["10.3233\/JAD-161207"],"URL":"https:\/\/doi.org\/10.3233\/jad-161207","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]}}}